Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merus NV

www.merus.nl

Latest From Merus NV

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

Bispecific Antibodies: US FDA May Require Comparison To Approved Monospecific Product

When approved therapies target the same antigens as the investigational bispecific antibody, FDA may request a comparative clinical trial, draft guidance notes.

Guidance Documents Biologics

China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.

StartUps and SMEs Companies

Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances

Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.

Innovation Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
      • Antibodies
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Merus BV
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Merus NV
  • Senior Management
  • Ton Logtenberg, PhD, Pres., CEO & Principal Fin. Officer
    Mark Throsby, PhD, EVP, CSO
    Hui Liu, PhD, EVP, CBO
    L. Andres Sirulnik, MD, PhD, EVP, CMO
  • Contact Info
  • Merus NV
    Phone: (31) 85 016 2500
    Yalelaan 62
    Utrecht , 3584 CM
    Netherlands
UsernamePublicRestriction

Register